Seasonal Affective Disorder; a Mood Disorder Characterized By Depression That Occurs At the Same Time Every Year

Seasonal Affective Disorder
Seasonal Affective Disorder

Seasonal Affective Disorder (SAD), also called major depressive disorder with seasonal pattern, is a form of depression. It is a mood disorder subset, in which people who have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year. It is another term for major depressive disorder (MDD) with seasonal pattern. It is a type of depression that is provoked by seasonal change. SAD most often occurs in women and young adults, particularly those who live farther north.

The Seasonal Affective Disorder Market is anticipated to reach US$ 544.7 million in 2020 and grow at a CAGR of 5.5% during the following five years (2020-2027).

This type of depression is related to changes in seasons and begins and ends at the same time every year. It is a type of depression that comes and goes in a seasonal pattern. SAD is sometimes known as winter depression because the signs and symptoms are usually more apparent and more severe during the winter. The treatment for SAD may include psychotherapy, light therapy, and medications. It is subtype of bipolar disorder. People diagnosed with bipolar disorder experience seasonal patterns in their symptoms.

SAD is a mental health condition that is triggered by the changing of the seasons. The risk of SAD increases with age. It's rare in people under age of 20. Women are affected more often than men. Thus, there is an increasing demand for safe & effective Seasonal Affective Disorder treatment. Antidepressants are thought to be most effective if taken at the start of winter before symptom appear, and continued until spring. SSRIs (Selective Serotonin Reuptake Inhibitors) are the preferred type of antidepressant for treating SAD.

Anticonvulsants Drugs were initially developed to treat epileptic patients. The primary symptoms of epilepsy are recurrent seizures, which are brief bursts of electrical activity in the brain that temporarily impede brain function.

Other types of antidepressants can also be used instead of SSRIs. APLENZIN is an antidepressant indicated for the prevention of SAD and treatment of MDD. It is the only FDA (the Food and Drug Administration) approved bupropion hydrobromide indicated for the prevention of SAD and offers more than 20 years of combined clinical experience in MDD and SAD.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more